• 1
    Gray BH, Conte MS, Dake MD, Jaff MR, Kandarpa K, Ramee SR, Rundback J, Waksman R. Atherosclerotic peripheral vascular disease symposium ii: lower-extremity revascularization: state of the art. Circulation 2008; 118: 286472.
  • 2
    Emmerich J. Current state and perspective on medical treatment of critical leg ischemia: gene and cell therapy. Int J Low Extrem Wounds 2005; 4: 23441.
  • 3
    Napoli C, Balestrieri A, Ignarro LJ. Therapeutic approaches in vascular repair induced by adult bone marrow cells and circulating progenitor endothelial cells. Curr Pharm Des 2007; 13: 324551.
  • 4
    Pearson JD. Endothelial progenitor cells – hype or hope? J Thromb Haemost 2009; 7: 25562.
  • 5
    Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc Interv 2007; 70: 47784.
  • 6
    Tongers J, Roncalli JG, Losordo DW. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc Res 2010; 79: 2006.
  • 7
    Critser PJ, Yoder MC. Endothelial colony-forming cell role in neoangiogenesis and tissue repair. Curr Opin Organ Transplant 2010; 15: 6872.
  • 8
    Yoder MC. Defining human endothelial progenitor cells. J Thromb Haemost 2009; 7: 4952.
  • 9
    Kahiguchi M, Kondo T, Izawa H, Kobayashi M, Yamamoto K, Shintani S, Numaguchi Y, Naoe T, Takamatsu J, Komori K, Murohara T. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007; 71: 196201.
  • 10
    Miyamoto K, Nishigami K, Nagaya N, Akutsu K, Chiku M, Kamei M, Sona T, Miyata S, Higashi M, Tanaka R, Nakutani T, Nonogi H, Takeshita S. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangitis obliterans. Circulation 2006; 114: 267984.
  • 11
    Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASCII). Eur J Vasc Endovasc Surg 2007; 33: S175.
  • 12
    Duong Van Huyen JP, Smadja DM, Bruneval P, Gaussem P, Dal-Cortivo L, Julia P, Fiessinger JN, Cavazzana-Calvo M, Aiach M, Emmerich J. Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. Mod Pathol 2008; 21: 83746.
  • 13
    Miller-Kasprzak E, Jagodzinski PP. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp 2007; 55: 24759.
  • 14
    Napoli C, William-Ignarro S, Byrns R, Balestrieri ML, Crimi E, Farzati B, Mancini FP, de Nigris F, Matarazzo A, D’Amora M, Abbondanza C, Fiorito C, Giovane A, Florio A, Varricchio E, Palagiano A, Minucci PB, Tecce MF, Giordano A, Pavan A, et al. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med 2008; 5: 5719.
  • 15
    Chavakis E, Urbich C, Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008; 45: 51422.
  • 16
    Hristov M, Weber C. Progenitor cell trafficking in the vascular wall. J Thromb Haemost 2009; 7: 314.
  • 17
    Khoo CP, Pozzilli P, Alison MR. Endothelial progenitor cells and their potential therapeutic applications. Regen Mec 2008; 6: 86376.
  • 18
    Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, Bieche I, Laurendeau I, Galy-Fauroux I, Fischer AM, Boisson-Vidal C. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008; 28: 64450.
  • 19
    Zemani F, Benisvy D, Galy-Fauroux I, Lokajczyk A, Colliec-Jouault S, Uzan G, Fischer AM, Boisson-Vidal C. Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem Pharmacol 2005; 70: 116775.
  • 20
    Boisson-Vidal C, Zemani F, Caligiuri G, Galy-Fauroux I, Colliec-Jouault S, Helley D, Fischer A-M. Neoangiogenesis induced by progenitor endothelial cells: effect of fucoidan from marine algae. Cardiovasc Hematol Agents Med Chem 2007; 5: 6779.
  • 21
    Senni K, Gueniche F, Foucault-Bertaud A, Igondjo-Tchen S, Fioretti F, Colliec-Jouault S, Durand P, Guezennec J, Godeau G, Letourneur D. Fucoidan a sulfated polysaccharide from brown algae is a potent modulator of connective tissue proteolysis. Arch Biochem Biophys 2006; 445: 5664.
  • 22
    Luyt CE, Meddahi-Pellé A, Ho-Tin-Noe B, Colliec-Jouault S, Guezennec J, Louedec L, Prats H, Jacob MP. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J Pharmacol Exp Ther 2005; 305: 2430.
  • 23
    Shireman P, Quinones M. Differential necrosis despite similar perfusion in mouse strains after ischemia. J Surg Res 2005; 129: 24250.
  • 24
    Zhu WH, Nicosia RF. The thin prep rat aortic ring assay: a modified method for the characterization of angiogenesis in whole mounts. Angiogenesis 2002; 5: 816.
  • 25
    Huang PH, Chen YH, Wang CH, Chen JS, Tsai HY, Lin FY, Lo WY, Wu TC, Sata M, Chen JW, Lin SJ. Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009; 29: 117984.
  • 26
    Hidalgo A., Peired AJ, Weiss LA, Katayama Y, Frenette PS. The integrin alphaMbeta2 anchors hematopoietic progenitors in the bone marrow during enforced mobilization. Blood 2004; 104: 9931001.
  • 27
    Bachelet L, Bertholon I, Lavigne D, Vassy R, Jandrot-Perrus M, Chaubet F, Letourneur D. Affinity of low-molecular-weight fucoidan for P-selectin triggers its binding to activated human platelets. Biochim Biophys Acta 2009; 1790: 1416.
  • 28
    Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME, Springer TA. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 1995; 128: 124353.
  • 29
    Alkhatib B, Freguin-Bouilland C, Lallemand F, Henry JP, Litzler PY, Marie JP, Richard V, Thuillez C, Plissonnier D. Low-molecular-weigth fucan prevents transplant coronaropathy in rat cardiac allograft model. Transpl Immunol 2006; 16: 149.
  • 30
    Shriver Z, Raguram S, Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Discov 2004; 3: 86373.
  • 31
    Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D. Low-molecular-weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem 2006; 281: 3784452.
  • 32
    Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 2003; 99: 4451.